Reevaluation difficult for Ildong and Abbott’s Lypsta
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.09.13 12:09:53
가나다라
0
Abbott conducted the bioequivalence tests in the approval process but Ildong submitted the Phase III trial results
Unclear whether the drug meets the price ceiling reevaluation criteria as well.. attention is focused on the court’s decision
There are slightly ambiguous aspects to Abbott Korea's ‘Lypsta Plus Tab,’ whose drug price was lowered on the 5th after the insurance price ceiling reevaluations.
This drug was jointly developed between Abbott Kore and Ildong Pharmaceutical, and the bioequivalence test data among the clinical trial data was submitted by Abbott.
Perhaps for this reason, Abbott opposed the price cut and filed for a stay of execution, due to which the drug price will be maintained as is the 28th.
According to industry sources on the 13th, The price of Lypsta Plus Tab’s 10/5mg formulation had been lowered from KRW 895 to KRW 761; the 10/10mg formulation from KRW 1,251 to KRW 1,063; and the 10/
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)